Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Joseph Klein III sold 2,250 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $53.56, for a total value of $120,510.00. Following the transaction, the director now owns 9,377 shares of the company’s stock, valued at $502,232.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Joseph Klein III also recently made the following trade(s):

  • On Monday, November 13th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $55.39, for a total value of $166,170.00.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded down $0.21 on Friday, hitting $54.15. The company had a trading volume of 416,997 shares, compared to its average volume of 1,494,890. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21. Ionis Pharmaceuticals, Inc. has a 52-week low of $37.26 and a 52-week high of $65.51. The stock has a market capitalization of $6,760.00, a PE ratio of 356.87 and a beta of 2.89.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/17/ionis-pharmaceuticals-inc-ions-director-joseph-klein-iii-sells-2250-shares.html.

A number of research firms have recently commented on IONS. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 price objective for the company in a research report on Tuesday, October 17th. Needham & Company LLC restated a “buy” rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a research report on Tuesday, October 17th. Stifel Nicolaus restated a “hold” rating and issued a $50.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. Goldman Sachs Group, Inc. (The) restated a “sell” rating and issued a $30.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday, October 6th. Finally, Barclays PLC began coverage on Ionis Pharmaceuticals in a research report on Wednesday, September 6th. They issued an “equal weight” rating and a $55.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the stock. Ionis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $50.31.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Ionis Pharmaceuticals by 4.4% during the second quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after purchasing an additional 417,364 shares in the last quarter. BlackRock Inc. boosted its stake in Ionis Pharmaceuticals by 4.0% during the second quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after buying an additional 264,179 shares during the last quarter. American Century Companies Inc. boosted its stake in Ionis Pharmaceuticals by 33.0% during the third quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after buying an additional 284,266 shares during the last quarter. First Trust Advisors LP boosted its stake in Ionis Pharmaceuticals by 40.2% during the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after buying an additional 281,733 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Ionis Pharmaceuticals by 7.8% during the second quarter. Northern Trust Corp now owns 621,816 shares of the company’s stock worth $31,631,000 after buying an additional 44,750 shares during the last quarter. Hedge funds and other institutional investors own 88.98% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.